(449) Triple-strengthened formulation for oral delivery of liraglutide-loaded nanoparticles

Introduction: Diabetes, including type 2, affects around 800 million people globally as of 2022, a fourfold rise since 1990. liraglutide, a GLP-1 receptor agonist, is effective in glycemic control and weight loss, with potential for treating Parkinson’s and Alzheimer’s. However, its injectable form limits patient compliance. This study explores oral delivery using nanoparticles of zein, Eudragit RS100, and chitosan. Zein provides biocompatibility, Eudragit RS100 ensures drug stability, and chitosan enhances bioavailability via mucoadhesion, enabling effective liraglutide delivery.